BioCentury
ARTICLE | Financial News

InflaRx raises EUR 31M in series C

July 21, 2016 7:00 AM UTC

InflaRx GmbH (Jena, Germany) raised EUR 31 million ($34.3 million) in a series C round. New investors included Staidson Hongkong Investment Co. Ltd., international industrial investors and family offices. Existing investors also participated.

Last month, InflaRx started the Phase II CARDIAC study of its IFX-1 to prevent severe systemic inflammation and organ dysfunction in patients undergoing complex cardiac surgery. The candidate is a humanized mAb targeting complement 5a (C5a), which is produced in large amounts during the early stages of an infection. ...